Avis Budget

Recent news

• Rating change
  U.S. Stocks Move | Alibaba R&D shares rise 2.37% in pre-market trading; Oppenheimer reaffirms Buy rating and $500 price target
  Gelonghui Finance · 2026/6/24
• European figures question whether U.S. firms' proposal to slow AI R&D is driven by "self-interest"
  Breakings · 2026/9/19
• Rating change
  Maiwei Biotech-U (688062): Independent R&D Lays the Foundation; BD Heyuan Drives Innovation, Efficiently Realizing Value Through Dual Engines
  Zhongtai Securities · 2026/2/25
• Company notice
  SanBio: [Delayed] Notice Regarding Integration of AKUUGO(R) Manufacturing Operations in Japan Following Closure of Minaris’ U.S. Facility
  JPX · 2026/9/7
• Rating change
  Qi An Xin-U (688561): Revenue under pressure but losses narrow; “4+1” R&D architecture positions for future growth
  Zhongtai Securities · 2026/9/10
• Rating change
  BeiGene (688235): Strong U.S. Market Performance and Efficient Advancement of Solid Tumor R&D
  China Post Securities · 2026/8/7
• In-Depth Research Report on Enflame Technology-U (688801): Full-Stack In-House R&D Builds Computing Power Foundation, 10,000-GPU Cluster Opens New Chapter in AI
  Huachuang Securities · 2026/9/23
• Company notice
  BOCOM N2809-R: Notice of Listing on The Stock Exchange of Hong Kong Limited - Bank of Communications Co., Ltd. Hong Kong Branch - Issue of CNY4,350,000,000 1.60 per cent. Notes due 2028 under its U.S. $12,000,000,000 Medium Term Note Programme
  HKEX · 2026/9/30
• Rating change
  Maiwei Bio-U (688062): A number of BD landing companies have strong R&D capabilities
  Caitong Securities · 2025/10/31
• Jacobs Selected By Nvidia To Deploy Its Data Center Digital Twin For A Large-Scale U.S. R&D Facility Under Three-Year Software-As-A-Service Deal; Terms Not Disclosed
  Benzinga · 2026/9/30
• Rating change
  Frontage Bio-U (688221): Steady Performance, Breakthrough in R&D
  Changjiang Securities · 2026/5/19
• Company notice
  ADV I N2908-R: Notice of Listing on The Stock Exchange of Hong Kong Limited - CNY2,000,000,000 1.86 per cent. guaranteed notes due 2029 of Advance I (BVI) Limited under the U.S.$1,000,000,000 Medium Term Note Programme
  HKEX · 2026/8/12
• Rating change
  Major Bank Ratings | JPMorgan: Expectation of Continued Easing in U.S.-China Relations Benefits Mainland Pharmaceutical R&D Outsourcing Industry
  Gelonghui Finance · 2025/12/5
• Rating change
  China Information Technology Mobile-U (688387): Continuously Increasing R&D Investment to Solidify Its Leading Position in Satellite Internet
  CICC · 2026/4/27
• Rating change
  Zejing Pharmaceutical-U (688266): Commercialization volume meets market expectations, multiple breakthroughs in R&D pipeline
  CSC Financial · 2025/11/15
• Company notice
  ADV I N2908-R: Publication of Offering Circular and Pricing Supplement - CNY2,000,000,000 1.86 per cent. guaranteed notes due 2029 of Advance I (BVI) Limited under the U.S.$1,000,000,000 Medium Term Note Programme
  HKEX · 2026/8/13
• Chemours Unterstützt Die Forderung Der Automobilindustrie Nach Einer Verlängerung Der Übergangsfrist Für Fluorierte Kältemittel in Mobilen Klimaanlagen (MAC) in Der EU Über Das Jahr 2040 Hinaus
  PR Newswire · 2026/9/28
• Company notice
  NYLIM U.S. Large Cap R&D Leaders ETF | 497K: Others
  SEC · 2026/8/28
• The Politicization of the U.S. Pharmaceutical Industry: Monitoring Clinical Trials in China While Attracting R&D Back Home
  Guancha Syndicate · 2026/9/17
• Rating change
  Zhongtai Securities: Maintains 'Buy' rating for 3SBio (01530), with early-stage R&D pipeline encompassing multiple first-in-class (FIC) candidates filed in both China and the U.S.
  Zhitong Finance · 2026/5/15

Headlines are aggregated automatically and are not independently verified or edited by our team.